Now, don’t get me wrong — we’re no fans of Martin Shkreli.
But we owe him credit for doing something right. In 2014, he complained to the feds — specifically the Federal Trade Commission — about a drug company’s anticompetitive behavior.
That company is called Mallinckrodt Pharmaceuticals, or MNK, and it was recently forced to pay a $100 million fine for squashing competition of its blockbuster drug, Acthar.
This merits discussion because MNK’s problems didn’t end with that payment.
The Emergency Election Sale is now live! Get 30% to 60% off our most popular products today!